FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963015968> ?p ?o ?g. }

• W1963015968 endingPage "h2219" @default.
• W1963015968 startingPage "h2219" @default.
• W1963015968 abstract "<b>Objective</b> To show non-inferiority of trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of severe infections due to meticillin resistant <i>Staphylococcus aureus</i> (MRSA). <b>Design</b> Parallel, open label, randomised controlled trial. <b>Setting</b> Four acute care hospitals in Israel. <b>Participants </b>Adults with severe infections caused by MRSA susceptible to trimethoprim-sulfamethoxazole and vancomycin. Patients with left sided endocarditis, meningitis, chronic haemodialysis, and prolonged neutropenia were excluded. <b>Interventions </b>Trimethoprim-sulfamethoxazole 320 mg/1600 mg twice daily versus vancomycin 1 g twice daily for a minimum of seven days and then by indication. <b>Main outcome measures </b>The primary efficacy outcome was treatment failure assessed at day 7, consisting of death, persistence of haemodynamic instability or fever, stable or worsening Sequential Organ Failure Assessment score, and persistence of bacteraemia. The primary safety outcome was all cause mortality at day 30. Non-inferiority was defined by a difference of less than 15% for treatment failure. <b>Results </b>252 patients were included in the trial, of whom 91 (36%) had bacteraemia. No significant difference in treatment failure was seen for trimethoprim-sulfamethoxazole (51/135, 38%) versus vancomycin (32/117, 27%)—risk ratio 1.38 (95% confidence interval 0.96 to 1.99). However, trimethoprim-sulfamethoxazole did not meet the non-inferiority criterion—absolute difference 10.4% (95% confidence interval −1.2% to 21.5%). For patients with bacteraemia, the risk ratio was 1.40 (0.91 to 2.16). In a multivariable logistic regression analysis, trimethoprim-sulfamethoxazole was significantly associated with treatment failure (adjusted odds ratio 2.00, 1.09 to 3.65). The 30 day mortality rate was 32/252 (13%), with no significant difference between arms. Among patients with bacteraemia, 14/41 (34%) treated with trimethoprim-sulfamethoxazole and 9/50 (18%) with vancomycin died (risk ratio 1.90, 0.92 to 3.93). <b>Conclusions </b>High dose trimethoprim-sulfamethoxazole did not achieve non-inferiority to vancomycin in the treatment of severe MRSA infections. The difference was particularly marked for patients with bacteraemia. <b>Trial registration</b> Clinical trials NCT00427076." @default.
• W1963015968 created "2016-06-24" @default.
• W1963015968 creator A5015397262 @default.
• W1963015968 creator A5018242728 @default.
• W1963015968 creator A5032461820 @default.
• W1963015968 creator A5035946224 @default.
• W1963015968 creator A5062405943 @default.
• W1963015968 creator A5071945493 @default.
• W1963015968 creator A5073576936 @default.
• W1963015968 creator A5078853283 @default.
• W1963015968 creator A5087472982 @default.
• W1963015968 creator A5089200309 @default.
• W1963015968 date "2015-05-14" @default.
• W1963015968 modified "2023-10-16" @default.
• W1963015968 title "Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial" @default.
• W1963015968 cites W164387411 @default.
• W1963015968 cites W1813389493 @default.
• W1963015968 cites W1969798675 @default.
• W1963015968 cites W1975122042 @default.
• W1963015968 cites W1979605679 @default.
• W1963015968 cites W1989586079 @default.
• W1963015968 cites W1990686237 @default.
• W1963015968 cites W2001280008 @default.
• W1963015968 cites W2002249283 @default.
• W1963015968 cites W2020611199 @default.
• W1963015968 cites W2021736141 @default.
• W1963015968 cites W2027256747 @default.
• W1963015968 cites W2043567648 @default.
• W1963015968 cites W2047830531 @default.
• W1963015968 cites W2048993021 @default.
• W1963015968 cites W2056229483 @default.
• W1963015968 cites W2071918548 @default.
• W1963015968 cites W2096132211 @default.
• W1963015968 cites W2102424776 @default.
• W1963015968 cites W2108433768 @default.
• W1963015968 cites W2111995886 @default.
• W1963015968 cites W2113811149 @default.
• W1963015968 cites W2117744797 @default.
• W1963015968 cites W2121499305 @default.
• W1963015968 cites W2121825896 @default.
• W1963015968 cites W2136091414 @default.
• W1963015968 cites W2137175695 @default.
• W1963015968 cites W2137692381 @default.
• W1963015968 cites W2138566304 @default.
• W1963015968 cites W2141620414 @default.
• W1963015968 cites W2150079902 @default.
• W1963015968 cites W2152602753 @default.
• W1963015968 cites W2155301516 @default.
• W1963015968 cites W2157962557 @default.
• W1963015968 cites W2159917073 @default.
• W1963015968 cites W2160965998 @default.
• W1963015968 cites W2171608016 @default.
• W1963015968 cites W2327037009 @default.
• W1963015968 cites W4214754383 @default.
• W1963015968 doi "https://doi.org/10.1136/bmj.h2219" @default.
• W1963015968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4431679" @default.
• W1963015968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25977146" @default.
• W1963015968 hasPublicationYear "2015" @default.
• W1963015968 type Work @default.
• W1963015968 sameAs 1963015968 @default.
• W1963015968 citedByCount "107" @default.
• W1963015968 countsByYear W19630159682015 @default.
• W1963015968 countsByYear W19630159682016 @default.
• W1963015968 countsByYear W19630159682017 @default.
• W1963015968 countsByYear W19630159682018 @default.
• W1963015968 countsByYear W19630159682019 @default.
• W1963015968 countsByYear W19630159682020 @default.
• W1963015968 countsByYear W19630159682021 @default.
• W1963015968 countsByYear W19630159682022 @default.
• W1963015968 countsByYear W19630159682023 @default.
• W1963015968 crossrefType "journal-article" @default.
• W1963015968 hasAuthorship W1963015968A5015397262 @default.
• W1963015968 hasAuthorship W1963015968A5018242728 @default.
• W1963015968 hasAuthorship W1963015968A5032461820 @default.
• W1963015968 hasAuthorship W1963015968A5035946224 @default.
• W1963015968 hasAuthorship W1963015968A5062405943 @default.
• W1963015968 hasAuthorship W1963015968A5071945493 @default.
• W1963015968 hasAuthorship W1963015968A5073576936 @default.
• W1963015968 hasAuthorship W1963015968A5078853283 @default.
• W1963015968 hasAuthorship W1963015968A5087472982 @default.
• W1963015968 hasAuthorship W1963015968A5089200309 @default.
• W1963015968 hasBestOaLocation W19630159681 @default.
• W1963015968 hasConcept C126322002 @default.
• W1963015968 hasConcept C141071460 @default.
• W1963015968 hasConcept C2777052132 @default.
• W1963015968 hasConcept C2778980435 @default.
• W1963015968 hasConcept C2779425571 @default.
• W1963015968 hasConcept C2779489039 @default.
• W1963015968 hasConcept C2780728791 @default.
• W1963015968 hasConcept C44249647 @default.
• W1963015968 hasConcept C501593827 @default.
• W1963015968 hasConcept C523546767 @default.
• W1963015968 hasConcept C54355233 @default.
• W1963015968 hasConcept C71924100 @default.
• W1963015968 hasConcept C86803240 @default.
• W1963015968 hasConcept C89423630 @default.
• W1963015968 hasConceptScore W1963015968C126322002 @default.
• W1963015968 hasConceptScore W1963015968C141071460 @default.

• next